期刊文献+

我国各地基本药物增补情况分析 被引量:1

Analysis of the situation of additional essential medicines in Chinese different regions
下载PDF
导出
摘要 目的:了解我国各地基本药物增补数量及其种类,为各地及国家制定和调整基本药物增补目录提供信息和依据。方法:采用直线相关分析法分析各省基本药物增补量与当地人均国民生产总值(GDP)之间的关系;采用频数分析法比较样本省增补的基本药物的数量、类别、品名等方面的同异等。结果:各省增补的基本药物数量与当地的人均GDP呈正相关(r=0.575,P=0.001);样本省增补的化学药品和生物制品中,抗微生物药品占增补总数的13.91%,中成药中清热剂占增补总数的18.17%;有59种药品被6个以上的省份增补,其中化学药品和生物制品有43种,中成药有16种。结论:社会经济状况影响各地基本药物的增补数量,各地基本药物的增补存在较为明显的趋同性,并以抗微生物药和清热剂的增补为主。 Objective: To provide information and evidence for framing and optimizing additional essential medicine lists(AEMLs) by investigating the amounts and categories of additional essential medicines (AEMs) in different regions of China. Methods: The rela tionship between the amount of AEMs and the local per capita gross domestic product(GDP) was analyzed by linear correlation method. The differences of amounts, categories and names, etc. of AEMs in different provinces were compared by frequency analysis. Results: Positive relation between the amount of AEMs and the local per capita GDP(r= 0. 575, P= 0. 001) was observed. In the additional chemical drugs and biological products of sample provinces,the antimicrobial agents accounted for 13.91%,and the heat clearing pre- scriptions accounted for 18.17% among the Chinese patent medicines. Fifty-nine drugs were added to the lists in more than 6 provinces, including 43 kinds of chemical drugs and biological products and 16 kinds of the Chinese patent medicines. Conclusion: The amount of AEMs is affected by the local social and economical conditions. Obvious convergence of AEMs in different regions is observed. The AEMs are mainly antimicrobial agents and the heat-clearing prescriptions.
出处 《药学服务与研究》 CAS CSCD 2012年第2期90-93,共4页 Pharmaceutical Care and Research
基金 2011年度福建省社会科学规划项目(No.2011B113)
关键词 基本药物 增补情况 人均GDP essential medicines additional situation per capita GDP
  • 相关文献

参考文献9

  • 1耿劲松,董建成,蒋葵,倪衡建,陈亚兰,吴辉群,张楚杰,包悦琪.我国基层医疗卫生机构增补药物目录的循证分析[J].中国循证医学杂志,2011,11(1):35-38. 被引量:9
  • 2景录先.合理选用中成药治疗感染性疾病[J].中国执业药师,2005(8):18-20. 被引量:5
  • 3李爽,纪佳.谈合理使用中成药[J].中国当代医药,2011,18(12):102-104. 被引量:10
  • 4世界卫生组织.基本药物[EB/OL].[2011-11-04]. http://www.who.int/mediacentre/factsheets/fs325/zh/.
  • 5李洋.光华卫生经济论坛聚焦国家医药制度建构[EB/OL].(2011-04—11)[2011-06—05].http://www.chinadaily.com.cn/zgrbjx/201104/11/content_12305813.htm.
  • 6中华人民共和国国家统计局.中国统计年鉴(2010)[EB/OL].(2010—09—26)[2011-04—07].http://www.stats.gov.cn/tjsj/ndsj/2010/html/D0304c.htm.
  • 7王秋冬.建立国家基本药物制度应注意八大问题[EB/OL].(2009—02—06)[2011-04—20].http://www.jkb.com.cn/document.jsp?docid=72174.
  • 8中华人民共和国卫生部.2010年中国卫生统计年鉴[EB/OL].(2010—10—08)[2011-04-01].http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/index2010.html.
  • 9王进学.增补非目录药品也需指导规范[N].中国医药报,2009—11—26(1308).

二级参考文献15

  • 1国家九部委.关于建立国家基本药物制度的实施意见[EB/OL].(2009-08-18)[2010-10-20].http://www.gov.cn/gzdt/2009-08/18/content_1395423.htm.
  • 2国家九部委.国家基本药物目录管理办法(暂行)[EB/OL].(2009-08-18)[2010-10-20].http://www.moh.gov.cn/publicfiles/business/htmlfileslmohywzc/s3581/200908/42512.htm.
  • 3卫生部.国家基本药物目录(基层医疗卫生机构配备使用部分)(2009版)[EB/OL].(2009-08-18)[2010-10-20].http://www.gov.cn/gzdt/2009-08/18/content_1395524.htm.
  • 4卫生部.2010中国卫生统汁年鉴[EB/OL].(2010-10-08)[2010-10-16].http://www.mob.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year20lO/index2010.html.
  • 5Wertheimer AI, Santella TM. Innovation and the WHO's essential medicines list: giving credit where credit is due. Res Social Adm Pharm, 2007, 3(1): 137-144.
  • 6Chen W, Tang S, Sun I, et al. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res, 2010, 10:211.
  • 7中华人民其和国国家统计局.中华人民共和国2009年国民经济和社会发展统计公报[EB/OL].(2010-02-25)[2010-10-20].http://WWW.stats.gov.cn/Ogb/ndOgb/qgndqgb/t20100225_402622945.htm.
  • 8陆丽珠,翟胜利.合理选用中成药[M],北京:北京科学技术出版社,2010:153-154.
  • 9李彤.谈中药的合理使用[J].中外医疗,2009,28(7):77-77. 被引量:1
  • 10冉建新.常用中成药合理应用的初探[J].中国当代医药,2009,16(17):88-89. 被引量:8

共引文献23

同被引文献18

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部